Within the OMITERC prospective study (OMIcs application from solid to liquid biopsy for a personalised ThERapy of Cancer), we explored the prognostic role of liquid biopsy encompassing cell-free DNA (cfDNA) and circulating tumour cells (CTCs) in KRAS mutated metastatic colorectal cancer (mCRC).
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study / Salvianti, Francesca; Gelmini, Stefania; Mancini, Irene; Pazzagli, Mario; Pillozzi, Serena; Giommoni, Elisa; Brugia, Marco; Di Costanzo, Francesco; Galardi, Francesca; De Luca, Francesca; Castiglione, Francesca; Messerini, Luca; Pinzani, Pamela; Antonuzzo, Lorenzo. - In: BRITISH JOURNAL OF CANCER. - ISSN 1532-1827. - STAMPA. - 125:(2021), pp. 94-100. [10.1038/s41416-021-01399-6]
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study
Salvianti, Francesca;Gelmini, Stefania;Mancini, Irene;Pazzagli, Mario;Pillozzi, Serena;Giommoni, Elisa;Brugia, Marco;Galardi, Francesca;De Luca, Francesca;Castiglione, Francesca;Messerini, Luca;Pinzani, Pamela;Antonuzzo, Lorenzo
2021
Abstract
Within the OMITERC prospective study (OMIcs application from solid to liquid biopsy for a personalised ThERapy of Cancer), we explored the prognostic role of liquid biopsy encompassing cell-free DNA (cfDNA) and circulating tumour cells (CTCs) in KRAS mutated metastatic colorectal cancer (mCRC).
| File | Dimensione | Formato | |
|---|---|---|---|
|
s41416-021-01399-6.pdf
Open Access dal 06/05/2022
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
466.25 kB
Formato
Adobe PDF
|
466.25 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
